Use of denosumab in a patient with non-small-cell lung cancer and severe renal function impairment

Journal of Thoracic Oncology

Volumn 8, Issue 6, 2013, Pages

  Govaerts, E ^a   Vansteenkiste, J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; DENOSUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; VITAMIN D;

AGED; BONE DISEASE; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC KIDNEY FAILURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CREATININE CLEARANCE; DISEASE SEVERITY; GRAFT REJECTION; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; HYDRATION; HYPERPARATHYROIDISM; KIDNEY DISEASE; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALE; MEDIASTINUM LYMPH NODE; PRIORITY JOURNAL; SHORT SURVEY; TUMOR LYSIS SYNDROME; VITAMIN SUPPLEMENTATION;

EID: 84879480014     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318284375c     Document Type: Article

References (6)

1. Coiffier B. Acute tumor lysis syndrome - a rare complication in the treatment of solid tumors. Onkologie 2010;33:498-499.
2. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011;364:1844-1854.
3. Dougall WC. Molecular pathways: osteoclast-dependent and osteoclastindependent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 2012;18:326-335.
4. Miller R, Jones J, Tometsko M, et al.: RANKL inhibition blocks lung cancer- induced osteolytic lesions and reduces skeletal tumor burden in both RANK-expressing and RANK-negative lung cancers. J Bone Miner Res 22 Suppl:114S, 2007
5. Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012;7:1823-1829.
6. Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 2011;26:1829-1835.